NEUROVIVE PHARM. AK News

0,418 +11,02% +0,0415 €
08:09 Uhr Frankfurt | Orderbuch | Mehr Kurse »
WKN: A0X93Z
ISIN: SE0002575340
Typ: Aktie

NEUROVIVE PHARM. AK News

  
Mo NeuroVive Out-​licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics PR Newswire
Mo NeuroVive Out-​licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics PR Newswire
31.05.18 Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire
31.05.18 Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire
22.05.18 NeuroVive Pharmaceutical AB Interim Report January - March 2018 PR Newswire
22.05.18 NeuroVive Pharmaceutical AB Interim Report January - March 2018 PR Newswire
21.05.18 NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development PR Newswire
21.05.18 NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development PR Newswire
02.05.18 NeuroVive Initiates Collaboration With Leading US TBI Research Organization PR Newswire
02.05.18 NeuroVive Initiates Collaboration With Leading US TBI Research Organization PR Newswire
27.04.18 Amendment: Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ) PR Newswire
27.04.18 Amendment: Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ) PR Newswire
27.04.18 Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ) PR Newswire
27.04.18 Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ) PR Newswire
27.04.18 Preferential Rights Issue in NeuroVive Oversubscribed PR Newswire
20.04.18 NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference PR Newswire
20.04.18 NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference PR Newswire
20.04.18 NeuroVive's Board Members, Senior Executives and Employees Will Subscribe Units in the Ongoing Rights Issue PR Newswire
20.04.18 NeuroVive's Board Members, Senior Executives and Employees Will Subscribe Units in the Ongoing Rights Issue PR Newswire
18.04.18 NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases PR Newswire
18.04.18 NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases PR Newswire
17.04.18 NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment PR Newswire
17.04.18 NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment PR Newswire
20.02.18 NeuroVive Pharmaceutical AB Year End Report January - December 2017 PR Newswire
20.02.18 NeuroVive Pharmaceutical AB Year End Report January - December 2017 PR Newswire
15.02.18 Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ) PR Newswire
15.02.18 Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ) PR Newswire
15.02.18 NeuroVive Decides on a Rights Issue for Continued Drug Development PR Newswire
15.02.18 NeuroVive Decides on a Rights Issue for Continued Drug Development PR Newswire
29.01.18 NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project PR Newswire
29.01.18 NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project PR Newswire
03.01.18 NeuroVive to Present at the 10th Annual Biotech Showcase Conference PR Newswire
03.01.18 NeuroVive to Present at the 10th Annual Biotech Showcase Conference PR Newswire
13.12.17 NeuroVive's KL1333 Program Granted Orphan Drug Designation by the European Commission PR Newswire
13.12.17 NeuroVive's KL1333 Program Granted Orphan Drug Designation by the European Commission PR Newswire
11.12.17 NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333 PR Newswire
11.12.17 NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333 PR Newswire
30.11.17 Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire
30.11.17 Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire
30.11.17 NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone PR Newswire
30.11.17 NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone PR Newswire
21.11.17 NeuroVive Pharmaceutical AB Interim Report January - September 2017 PR Newswire
21.11.17 NeuroVive Pharmaceutical AB Interim Report January - September 2017 PR Newswire
15.11.17 NeuroVive Presents TBI Clinical Study Results at Nordic Neurotrauma Conference PR Newswire
15.11.17 NeuroVive Presents TBI Clinical Study Results at Nordic Neurotrauma Conference PR Newswire
07.11.17 NeuroVive Board Chair Resigns, New Chair Elected PR Newswire
07.11.17 NeuroVive Board Chair Resigns, New Chair Elected PR Newswire
03.11.17 NeuroVive Conducts a Directed New Share Issue of SEK 5.3 Million PR Newswire
03.11.17 NeuroVive Conducts a Directed New Share Issue of SEK 5.3 Million PR Newswire
31.10.17 NeuroVive Signs Collaboration Agreement With University of Florida for TBI Biomarker Development PR Newswire

Newssuche

  

Videos

  
06:41 Uhr
NYSEinstein am 19.6.2018: "Kluge Männer bauen Brücken, dumme bauen Mauern"